Lepton Pharmaceuticals LTD a pre-commercial-stage biopharmaceutical company focused on development proprietary gene editing based treatments for primarily oncology indications, is pleased to announce that it signed a Master Service Agreement with Reaction Biology for providing drug development services for advancing Lepton’s proprietary breakthrough Castling technology based novel treatments for oncology  indications.

The Castling Technology is a proprietary miRNA, gene editing based, method to improve CAR- T cells and other immune cells persistence and cytotoxicity for treatment of various types of cancer,

Reaction Biology was founded in 2001 and provides a full suite of preclinical drug discovery services to over 1800 customers worldwide, including a wide range of mechanistic and biophysical study options, an extensive array of cellular oncology models, and an animal facility focusing on oncology models. It maintains lab facilities in Malvern, PA, and Freiburg, Germany.